PanGenomic Health Admitted to Trading on the AQSE Growth Market in London, United Kingdom
VANCOUVER, BC, April 12, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to announce that it has completed its admission to the Access segment of the Aquis Stock Exchange ("AQSE") and trading will commence at 8:00 a.m. GMT on April 12, 2023 under the ticker "NARA" and with its existing ISIN CA 69842E 20 5 0. The Company's shares will also continue to trade on the Canadian Securities Exchange ("CSE").
IPub loves NARA.. a little indirectly but do try and keep up ;):
ADVFN has just named Yellow Jersey PR the Best Financial PR Agency in its International Financial Awards. Thanks to our clients, the brokers, nomads and advisers we work with, and congratulations to the other winners.
VANCOUVER, BC, March 30, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA), is pleased to announce its subsidiary, MUJN Diagnostics Inc. ("MUJN Diagnostics"), has signed a master services agreement with Hemex Health Inc. ("Hemex Health"), a Portland, Oregon-based medical diagnostic device company focused on developing life changing testing solutions for the point-of-care market. Hemex Health will assist MUJN Diagnostics in developing a diagnostics system, which can be used to support patients being treated with alternative therapies for brain health. This system will objectively track the efficacy of a patient's treatment program. As part of this engagement, MUJN Diagnostics will develop proprietary brain biomarker diagnostic panels, and Hemex Health will enhance their Gazelle point of care platform ("Gazelle") to analyze these tests. In March 2023, MUJN Diagnostics and Hemex Health initiated the diagnostic cartridge design phase of the engagement.
what do you think of the "science" that claims these herbs that may boost your dopamine levels; Ginseng, Ginkgo biloba, Rhodiola rosea, St. John’s wort and Mucuna pruriens?..
As an AI language model, I don't have personal opinions or beliefs. However, I can provide some information about the scientific evidence regarding the herbs you mentioned and their potential effects on dopamine levels.
Dopamine is a neurotransmitter in the brain that plays a role in regulating mood, motivation, and reward. While there is some evidence to suggest that certain herbs may have an impact on dopamine levels, the research in this area is limited and not always conclusive.
Here is what the current scientific literature says about the herbs you mentioned:
Ginseng: Some studies suggest that ginseng may increase dopamine levels in the brain, which could potentially have a positive effect on mood and cognitive function. However, more research is needed to fully understand this effect.
Ginkgo biloba: Ginkgo biloba has been shown to have antioxidant and anti-inflammatory properties, which may have a positive effect on brain function. While there is some evidence to suggest that ginkgo biloba may increase dopamine levels, the research in this area is limited and not always consistent.
Rhodiola rosea: Rhodiola rosea is an herb that is sometimes used as an adaptogen to help the body cope with stress. Some studies suggest that it may have a positive effect on dopamine levels, but more research is needed to fully understand this effect.
St. John’s wort: St. John’s wort is a herb that is often used to treat mild to moderate depression. While there is some evidence to suggest that it may increase dopamine levels in the brain, the research in this area is limited and not always conclusive.
Mucuna pruriens: Mucuna pruriens is an herb that contains L-DOPA, which is a precursor to dopamine. Some studies suggest that it may increase dopamine levels in the brain, but more research is needed to fully understand this effect.
It's worth noting that while these herbs may have some potential benefits, they can also have side effects and interactions with medications. It's important to talk to your doctor before taking any herbs or supplements, especially if you have any underlying health conditions or are taking medications.
PanGenomic Health Subsidiary Signs Rental Agreement with Psy Integrated Health, Makes Progress Towards Development of Joint Testing Facility VANCOUVER, BC, Feb. 2, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA), is pleased to announce that, further to the announcement made on January 26, 2023, its subsidiary, MUJN Diagnostics Inc. (formerly named PlantGx Diagnostics Corp.)("MUJN Diagnostics"), has signed an agreement to lease space at Psy Integrated Health, Inc.'s ("Psyi") Empower Health Wellness Centre clinic facility located in Vancouver, BC. This rental agreement represents an important step in the development of a proposed joint diagnostic testing facility with Psyi. "Co-locating a diagnostic testing facility at the Empower Health Wellness Centre is expected to help both MUJN and Psyi more effectively understand the needs of clients suffering from brain health challenges", said Vincent Lum, CEO of MUJN Diagnostics and Co-Founder of PanGenomic Health. "We believe the integrated health approach to patient wellness will continue to grow and provide positive outcomes to clients experiencing concerns with mental health." Patrick Callas, Director of Integrated Health, Psy Integrated Health, added: "We are excited to have MUJN Diagnostics in our wellness centre, and we believe the synergies of working together will result in innovative new ideas for better patient outcomes in alternative healthcare therapies." The rental agreement will cover an initial term of 6 months, ending August 1, 2023. Further to the Company's news release dated January 26, 2023, MUJN Diagnostics and Psyi are continuing to work towards a definitive agreement with respect to their proposed joint venture for the joint development of a brain health targeted biomarker diagnostics service to support clients being treated with ketamine assisted therapy. Additional details are expected to be announced upon the execution of a definitive agreement for the proposed joint venture. No assurances can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed joint venture will proceed in the timeframe currently contemplated or at all. About Psy Integrated Health Psy Integrated Health, Inc., with its flagship wellness centre Empower Health located in the heart of Vancouver, BC. Canada, is a clinic management services BC benefit company created to accelerate the development of psychedelic assisted therapeutic treatments and integrated health. Psyi provides innovative treatment modalities for clients with a variety of indications. More information can be found at www.psyintegrated.com and www.empowerhealth.ca. About MUJN Diagnostics MUJN Diagnostics Inc. is a wholly-owned subsidiary of PanGenomic Health Inc. and is focused on developing a decision support system for alternative healthcare providers. MUJN's Decision Support System includes biomarker diagnostics, symptom and treatment tracking, and personalized health analytics, with the goal of empowering healthcare providers and their patients towards better outcomes. About PanGenomic Health PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company's initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic Health's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual. https://sedar-filings-backup.thecse.com/00039388/2302020446213586.pdf